Phase 1 Trial of Ivosidenib for Patients with AML Boasts Positive Results
Researchers report positive results for phase 1 trial of ivosidenib in patients with IDH1+ acute myeloid leukemia.
Treatment at Specialized Cancer Center Linked with Improved Survival in Children with ALL
Results of a recent study demonstrate that treatment at a specialized cancer center is associated with better leukemia-specific survival in children, adolescents, and young adults.
New Treatment Regimens Boost Survival Rates in Children with T-ALL or T-LL
A new phase 3 clinical trial boasts highest survival rates of these T-cell malignancies.
Peptide Vaccine Demonstrates Safety & Immunogenicity in Patients with Astrocytomas
First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.
PVd Significantly Improves PFS in LEN-Exposed RR Multiple Myeloma Patients
To date, OPTIMISMM is the only phase 3 study in early RRMM to report a significantly and clinically meaningful PFS improvement in LEN-exposed patients.
Study Explores Tumor Genotyping in Patients Newly Diagnosed with Glioblastoma
Prospective genomics can inform subsequent clinical trial analysis aiming at matching outcome with tumor genotyping.
Physician and Patient Advocate Discuss Recent Drug Approval for Kidney Cancer
Saby George, MD, FACP, and Dena Battle, president of nonprofit patient advocacy group, KCCure, discussapproval of Opdivo (nivolumab) and Yervoy (ipilimumab) therpay combination for kidney cancer.
FDA Grants Astellas Pharma Inc Priority Review for Gilteritinib for Refractory AML
The US FDA has granted Astellas Pharma Inc priority review for gilteritinib for refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Genetic Testing Could Result in Life-Extending Treatment for Incurable Pediatric Brain Tumors
In an article recently published by the Institute of Cancer Research, genetic testing was indicated to result in life-extending treatment for incurable pediatric brain tumors.
Phase 3 OLYMPUS Trial Interim Analysis for UTUC Shows Efficacy
Yesterday, UroGen Pharma Ltd released positive data from its interim analysis of the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (MitoGel) for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC).
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.